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Abstract 
Background 
Localized prostate cancer affects patient’s quality of life in many ways. The aim of this 
study was to explore factors related to self-rated health and life satisfaction for patients 
treated for prostate cancer, and to compare the results of these generic quality of life 
measures to the prostate cancer specific quality of life measure (UCLA Prostate Cancer 
Index), which focuses on physical functioning. 
Material and methods 
This cross-sectional survey was carried out among 183 men who underwent radical 
prostatectomy in 2012–2015 at a university hospital in Finland, and were seen one year 
post-surgery. Approval from an ethics committee and written consents from participants 
were received. A questionnaire was used to evaluate patients’ perceived quality of life. 
Logistic regression model, Spearman’s correlation, Kruskall-Wallis test and Mann Whitney 
U test were used to analyze factors related to quality of life. 
Results 
Of the 183 men in the study, 63% rated their health status as good, and 70% were 
satisfied with their lives after prostatectomy. Older age and better urinary function were the 
only factors that explained both better self-rated health and better satisfaction with life. The 
patients seemed not to interpret problems with sexual function as health-related problems. 
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In our sample, sexual dysfunction was relatively severe, but patients considered them to 
be less harmful than urinary or bowel symptoms. Interestingly, 24% of the men with low 
sexual function did not find that dysfunction bothersome. 
Conclusions 
Objectively measured physical functioning is not necessarily in line with patients’ 
experienced satisfaction with life and their self-ratings of health. More longitudinal and 
qualitative research is needed about the meanings that patients attach to physical 
treatment side effects and the extent to which they can adapt to them over time. With a 
bigger sample and longer follow-up time it would be possible to identify men who 
particularly benefited from pre-treatment counselling. 
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Background 
In Nordic countries, nearly 25 000 new prostate cancer cases are diagnosed every year, 
which means that over 230 000 men are living with the diagnosis. In Finland alone, there 
are over 49 000 prostate cancer patients alive, and many of them receive therapy for their 
disease [1]. Prostate cancer treatment options vary according to the stage of the disease 
from radical alternatives, such as surgical removal of the prostate gland (prostatectomy) 
and radiation therapy, to hormone therapy and watchful waiting approach. Active 
surveillance is an option for patients with localized, low risk prostate cancer in which the 
patient has regular tests to monitor the cancer but not getting curative radical treatment 
unless needed. 
Active surveillance aims at avoiding unnecessary treatment, because radical treatment for 
prostate cancer often causes major side effects, most commonly urinary incontinence and 
erectile dysfunction, which may decrease many men’s health-related quality of life 
(HRQoL) permanently [2-4]. As prostate cancer survival rates are relatively high [5], coping 
with treatment side effects that affect a patient’s quality of life (QoL) is a major issue. 
Quality of life after prostate cancer treatment has typically been assessed either in terms 
of treatment side effects or through generic, non-disease specific QoL measures [3, 6-8]. 
Both measures have their limitations. General HRQoL instruments may not be sensitive 
enough to detect disease-specific changes in QoL. [9] Symptom-based QoL evaluation, in 
turn, does not take into account that patients’ may interpret same kind of ailments very 
differently. For instance, few or mild physical postoperative symptoms do not necessarily 
mean that the prostate cancer patient experiences a good overall quality of life or feels 
satisfied with his life after treatment. 
When measured only based on symptoms and functioning, a good quality of life before 
radical prostatectomy seems to predict better QoL after treatment; men with good urinary 
and sexual function preoperatively will more likely retain their functions better 
postoperatively [3, 10]. Preoperative symptom-based QoL is associated with the patient’s 
age, race, employment, and level of education: Younger, white, employed, and highly 
educated men have less incontinence and erectile dysfunction before surgery  [3].  
When evaluated based on a general HRQoL-measure, such as the SF-36 questionnaire  
[11] which includes four physical domains and four mental domains, treatment choice 
seems to affect patients’ general physical QoL, but general mental functioning is not 
greatly affected in early recovery period after treatment. [12] At least older age, absence of 
comorbidities, better education and income level, availability of social support and absence 
of social constraints seem to predict better general mental and physical functioning [12, 
13]. Also higher self-esteem and self-efficacy are associated with better general QoL in 
patients with localized prostate cancer. [12]  
Life satisfaction is a substantial part of the quality of life, and thus, treatment choice has 
been found to affect prostate cancer patients’ satisfaction with life. Patients treated with 
hormonal therapy are less satisfied with their lives than are other prostate cancer patients. 
Most satisfied are those patients treated with internal radiation therapy and patients under 
active surveillance. [14] Despite the higher satisfaction among active surveillance patients, 
however, both active surveillance and watchful waiting can cause anxiety, as the patient 
has to live with his cancer diagnosis without receiving immediate treatment [15, 16] 
HRQoL as a concept emphasises each patient’s own views and personal evaluation of his 
current health [17, 18], which is why self-rated health (SRH) is an important domain to 
measure. In a previous study, no treatment group differences were found in SRH between 
patients treated for localized prostate cancer. In addition, patients reported rather good 
general health despite their treatment choice. [12] SRH has been found to be an 
independent predictor of survival among prostate cancer patients [19] and in several 
different types of cancer. The most dramatic decreases in overall health in cancer patients 
occurs within the first year of cancer diagnosis when the patients are undergoing 
treatment. After this SRH begins to return to pre-cancer levels. Unlike in lung, breast, or 
colorectal cancer, prostate cancer patients do not experience same decline in SRH at the 
time of diagnosis, which is most probably due to earlier diagnosis and lesser symptoms at 
this time point. [20] 
To address the gap between these two different approaches to quality of life (symptom-
based vs general QoL), we measured HRQoL by evaluating patients’ self-rated health and 
satisfaction with life, and compared the results of these subjective assessments against a 
more objective (though self-reported) prostate cancer specific QoL-measure, which 
focuses on physical functioning. Our study questions were: 
1. What factors are associated with (a) self-rated health and (b) satisfaction with life one
year after radical prostatectomy? 
2. How do the associated factors differ for the Prostate Cancer Index, life satisfaction and
self-reported health? 
Material and methods 
A survey was conducted in 2012–2015 at a university hospital in Finland after the study 
received its approval from a regional ethics committee (R12025/ Apr 17th 2012). 
Approximately 500 prostate cancer patient (all treatment modalities included) are being 
cared in this hospital per year. Nurses working at the urology outpatient clinic gave a 
questionnaire and a consent form to the prostate cancer patients when they came to one-
year post-surgery check-up. Patients who were willing to participate after receiving 
information of the study filled in the questionnaire and written consent and returned them 
to their doctor. A total of 183 questionnaires were returned out of approximately 350 
questionnaires given to patients. 
We used the UCLA Prostate Cancer Index (UCLA PCI)  [9] to measure the prevalence of 
treatment side effects. UCLA PCI contains 20 disease-targeted items that evaluate urinary, 
sexual, and bowel function and symptom-related bother. Also patient-perceived treatment 
satisfaction was asked using an original UCLA PCI question. UCLA PCI has proved to 
have a good cross-cultural validity [9]. Additionally, we asked the patients about their 
perceptions about their health status, life satisfaction, sufficiency of patient guidance, and 
prevalence of pre-treatment erectile dysfunction. The used questions and distributions of 
patients’ answers to them are shown in Table 1. 
We used a single Likert-scale item of the questionnaire to assess SRH: “How would you 
rate your current health?”  [21] (Very good/ Fairly good/ Average/ Fairly poor/ Poor). 
Because our purpose was to distinguish men who clearly stated feeling healthy from those 
men who had a perception of having either average or even poorer health, we transformed 
the Likert-scale variable into binomial form.  In the new outcome variable, the patient was 
classified in group “Good SRH”, if he had answered “Fairly good” or “Very Good” to the 
question, and, the if he had answered something else, the patient was classified in group 
named “Average or poor health”. 
Following the same principle, we composed a binomial outcome variable for satisfaction 
with life. We used the question, “How satisfied are you with your life as it is?”  [22] to 
produce the outcome variable for life satisfaction. If the patient answered “Very satisfied” 
or “Satisfied”, he was classified in the group “Clearly satisfied”, and if he answered 
something else (Somehow satisfied/ Unsatisfied/ Very unsatisfied/ I don’t know), he was 
classified as “Less satisfied”.  
Although some information was lost by simplifying the data from multi-categorical into 
binomial format, these stratifications were more clinically relevant when assessing an 
interpretative topic, such as a patient’s self-reported quality of life. After all, in this study, 
the focus was to examine factors related to good SRH and clear satisfaction with life 
instead of general satisfaction level or health status. Similar categorization had also been 
used earlier in other prostate cancer studies  [19, 23, 24]. Also treatment satisfaction 
variable and pre-treatment erectile dysfunction variable were used in binomial form in the 
analyses.  
Data on age and cancer-related clinical characteristics (serum PSA level, tumor Gleason 
score, percentage of cancer tissue in biopsy sample, tumor T stage, tumor margin status, 
and treatment received) were collected from the hospital register. Tumor Gleason score 
determines the aggressiveness of the cancer: The higher the score is on scale from 2 to 
10, the more likely the cancer will spread.  Age, PSA (prostate specific antigen) level, and 
percentage of cancer tissue in the biopsy were used as continuous variables throughout 
the analysis, while other clinical characteristics were used in categorical form. Marital 
status and occupation were not systematically reported in the hospital register, so they had 
to be left outside the analysis. 
The relationships between categorical outcome variables and continuous explanatory 
variables were described using median, Q1, and Q3 and tested with Mann-Whitney U. We 
used cross-tabulation and Chi square test for the categorical explanatory variables. 
Univariate logistic regression analysis was performed to identify factors predicting good 
SRH and satisfaction with life. Independent variables that were significantly associated 
with either of the outcome variables in the univariate model were then further evaluated in 
a multivariate logistic regression model. We left the UCLA PCI bother scales out of the 
logistic regression models, for they correlated with the corresponding function variables. 
Also, the variables that considered received treatment (e.g., radiation therapy, hormonal 
therapy) had to be left outside all the analyses due to their small number of cases. All 
chosen variables were placed in the logistic regression model at the same time to control 
for confounding. 
We followed the scoring instructions of the UCLA PCI, and calculated average values for 
function and bother scales. UCLA PCI has only been validated as a continuous scale  [9], 
so the function and bother variables were used as continuous throughout the analysis. 
Spearman’s correlation, median, Q1, and Q3 were used to describe the association 
between explanatory variables and the PCI scores. Associations were tested using the 
Kruskall-Wallis test and the Mann Whitney U test. We chose p<0.05 as the threshold level 
for statistical significance. The data was analyzed using the IBM SPSS Statistics 23 
program. 
Results 
Characteristics of the respondents 
The study population consisted of 183 Finnish men being treated for prostate cancer. All 
men underwent radical prostatectomy as their primary treatment. Some patients (10%) 
were under active surveillance before radical treatment. The median time of active 
surveillance was 18 months. Five patients received anti-androgen therapy pre-operatively, 
as they were participating in a study of local anti-androgens effect on the prostate  [25]. 
Post-operatively, eight patients received radiation therapy, and endocrine treatment was 
carried out on four patients. 
The men were aged 48 to 75 years. Most patients (64%) had a Gleason score of 7, and all 
the patients had either localized (T2) or locally advanced (T3) prostate cancer (Table 1). 
Only two patients had lymph node involvement (stage N1). Blood PSA levels varied 
between the minimum of 1.3, and the maximum of 44.9 µg/l at the time of diagnosis. Most 
patients had a negative margin status in their tumor (Table 1). In the diagnostic biopsy 
samples, the percent of cancer tissue varied between <1% and 75%. 
(Table 1 here) 
In this study population, median scores for urinary function were clearly better than they 
were for sexual function, whereas median urinary function was clearly lower than median 
bowel function (see Table 1.). Urinary scale was the only scale in which median bother 
was worse than median function. The median values in urinary function and bother were 
parallel. Problems with bowel function and bother related to it were scarce among 
participants. Less than half of the men had experienced erectile dysfunction prior to 
treatment. A clear majority of patients were clearly satisfied (Very satisfied / Satisfied) with 
received cancer treatment and majority also felt that patient guidance offered had been 
sufficient. 
Factors related to SRH 
Most patients (63%) rated their health as good (Very or Fairly good) one year after 
prostatectomy (Table 1). As Table 2 shows, men who rated their health as good were 
older than men with average or poor SRH. Men with good SRH had higher PSA values 
and a lower percentage of cancer tissue in the diagnostic biopsy sample. There was no 
statistically significant difference between the two groups of patients in Gleason score, T 
stage, or margin status. Men who were clearly satisfied with cancer treatment were more 
likely to report good SRH. Experiencing patient guidance as sufficient was also more 
common in good SRH group, but the difference was not statistically significant. 
(Table 2 here) 
Men with good SRH had significantly better urinary and bowel function and bother scores 
than did men experiencing average or poor SRH. Also, their sexual function was superior, 
but the difference was not statistically significant. There was no difference in sexual bother 
between the two groups. As Table 2 shows, at least 25% of the men with good SRH 
experienced great bother from their sexual dysfunction (Q₁=0). Men who had never 
experienced pre-treatment erectile dysfunction usually rated their health status as good. 
In a multivariate logistic regression analysis, we found that higher age, higher preoperative 
PSA level, lower percentage of cancer tissue in biopsy sample, satisfaction with treatment, 
and better urinary function were statistically significantly associated with good SRH (see 
Table 3). 
(Table 3 here) 
Factors related to life satisfaction 
Of the participants in this study, 70% were clearly satisfied (Very satisfied or Satisfied) with 
their lives one year after prostatectomy (Table 1). As seen in Table 2, clearly satisfied men 
were older than less satisfied men. There was no statistically significant difference in the 
PSA, Gleason score, T stage, or margin status between the two groups, but less satisfied 
men did have a higher percentage of cancer tissue at their diagnostic biopsy. 
A clear satisfaction with cancer treatment was markedly more common among men clearly 
satisfied with their lives, similarly, being less satisfied with treatment was more common 
among men feeling less satisfied with life. Also, patient guidance was more commonly 
experienced as being sufficient among clearly satisfied men. 
Clearly satisfied men had better urinary, sexual, and bowel function and bother scores. 
Especially, sexual bother scores were markedly better among these men. Still, at least 
25% of clearly satisfied men experienced great bother from sexual dysfunction (Q₁=0). 
There was no statistically significant difference between the two groups in the prevalence 
of erectile dysfunction before cancer treatment. 
Using multivariate logistic regression analysis (see Table 3) we found that higher age and 
better urinary and sexual function were statistically significantly related to satisfaction with 
life one year after prostatectomy. Satisfaction with treatment was almost statistically 
significantly associated with life satisfaction. 
Factors related to urinary, sexual, and bowel function 
Men who were clearly satisfied with their received cancer treatment had significantly better 
urinary function than did less satisfied men (see Table 4.). Also men who perceived patient 
guidance as sufficient had better urinary function than did those men who did not. There 
was no association between urinary function and age, PSA, percentage of cancer tissue in 
biopsy, Gleason score, T stage, or margin status. 
(Table 4 here) 
Sexual function correlated with patient’s age and experienced sexual bother. In general, all 
correlations were weak. Still, older men had worse sexual function. (Table 4) All of the 
study participants had at least some erectile dysfunction, for the maximum sexual function 
score was only 88 among all study participants. Although sexual function clearly correlated 
with sexual bother (Table 4), 22 of the 92 men (24%) with very low sexual function (0-24 
function scores) experienced very little or no bother (75-100 bother scores) (data not 
shown). In terms of urinary or bowel function and bother, we did not find a similar group of 
men who reported experiencing little or no bother despite severe symptoms. 
Men with higher Gleason scores had significantly worse sexual function (Table 4.). Also, 
men who were satisfied with their cancer treatment had significantly better sexual function. 
Pre-treatment erectile dysfunction was also associated with sexual function: Men who 
reported having erectile dysfunction at least sometimes pre-operatively had clearly lower 
function one year after radical prostatectomy. Sexual function was not associated with 
serum PSA, percentage of cancer tissue in the biopsy sample, T stage, margin status, or 
perceived sufficiency of patient guidance. Bowel function was only associated with bowel 
bother. 
Discussion 
Our study showed that there were both similarities and differences in the factors related to 
our generic QoL-measures (SRH and life satisfaction) and UCLA PCI function domains. 
Satisfaction with treatment was associated with SRH, life satisfaction, sexual function, and 
urinary function. Clinical cancer characteristics had associations only with SRH and sexual 
function, but none of these characteristics were related to both of them. Older age, on the 
other hand, was associated with better self-rated health, higher life satisfaction, and worse 
sexual function, although age was not associated with urinary function. 
Older men felt healthier and more satisfied with their lives than did younger men despite 
treatment side effects. This finding is in line with Chambers et. al. study [13] that noted 
younger men being less satisfied with life after prostate cancer, which was assumed to 
derive from active careers, active sexual life and greater financial responsibilities. Also, in 
assessing their own health, people adjust these assessments to their age group’s 
assumed state of health. Therefore, younger men may interpret their dysfunctions more 
easily in terms of poor health when comparing themselves to age mates [26].  
There was a clear relationship between good sexual function and satisfaction with life. This 
result is easy to understand, for sexual capability and sexual activity are often seen as 
crucial aspects of masculine identity and the role of man  [27]. All participants in this study 
had some problems with sexual function, which was linearly associated to sexual bother. 
However, to our surprise, there were men who did not experience corresponding sexual 
bother from their severe sexual dysfunction. This result cannot be fully explained by 
endocrine treatment or anti-androgen therapy, for only nine patients received either of 
these. There were also some men who experienced substantial sexual bother, but they 
were still satisfied with their lives. It would be important to further study to what extent 
these associations between sexual function and bother and life satisfaction can be 
explained only in terms of patients’ age. 
Contradictions like these have been noted in earlier studies, where men reported good 
QoL despite the high prevalence of treatment side effects  [28]. More comprehensive 
knowledge of the patients’ background, such as marital status and family situation could 
partially help explain the contradiction we found. Unfortunately we were not able to collect 
data on these from the hospital register as we had presupposed. It would be plausible to 
suggest that men with a supportive partner will better adapt to erectile dysfunction, for 
partners often provide emotional support and encourage their men to seek rehabilitation 
activities.  [29-31]. 
We noted that the median sexual function was clearly lower than the median urinary 
function. Also, urinary incontinence impaired both SRH and life satisfaction, whereas even 
quite burdensome erectile dysfunction did not affect SRH. Apparently, men do not interpret 
problems with sexual function as a health issue in the same way that they do urinary 
incontinence. It is known that men tend to normalize erectile dysfunction caused by cancer 
treatment by interpreting the symptoms as part of the normal aging process and by stating 
that sexual activity is mainly part of a younger man’s life  [27, 28, 32-34]. This view may 
also explain why the participants of this study did not necessarily take erectile dysfunction 
into account when answering the general questions about their health  [28].  
Urinary incontinence caused by cancer treatment is not typically interpreted as an age-
related issue. Over time, patients adjust to their new, worse urinary function and find it 
fairly easily manageable [35]. In this study, the inquiry was conducted one year after 
prostatectomy, and therefore the patients had perhaps not been able to adapt to the 
symptoms yet, as the effect of urinary function on their SRH and life satisfaction was 
strong.  
However, life situation affects perceived urinary bother, which in earlier studies have been 
found to be independently related to satisfaction with life [24]. Urinary incontinence has a 
major impact especially on working-aged men. Men feel anxiety about hiding their physical 
impairment at work, and practical issues involved in maintaining dryness can cause 
emotional distress [36]. On the other hand, patients may feel grateful for being alive after 
cancer treatments, which makes urinary incontinence seem less of a problem than losing 
one’s life [28]. In case of prolonged side effects, however, treatment benefits, such as 
disease control, may also lose their importance for the patient if the side effects 
substantially complicate daily life [37]. 
 
A surprising result of our study was that men with a higher preoperative serum PSA level 
reported better self-rated health than did men with a lower PSA level. Similar findings have 
been reported earlier, where prostate cancer survivors who regretted their treatment 
choice had a less severe case of cancer based on PSA and Gleason score [38]. It is also 
known that prostate cancer patients tend to perceive their illness by using concrete 
numerical information  [39], and they keep track of their illness trajectory through their PSA 
level, often by comparing their test results with those of other men  [34, 40]. It thus 
appears plausible to suggest that men with higher PSA levels could experience less regret 
about treatment because they feel that there was no other choice than to have their cancer 
treated, regardless any possible treatment side effects. 
 
Our study has several limitations. Cross-sectional study design limits the ability to draw 
valid conclusions about possible causality. Therefore, a longitudinal design with a bigger 
sample is needed to confirm these associations. Secondly, there were wide confidence 
intervals for some of the variables related to SRH or satisfaction with life, although some of 
the relationships were statistically significant. The reason for these wide confidence 
intervals was partly due to the small number of participants (n=183). Also, almost all 
correlation coefficients were low. Certain demographic parameters (family situation, marital 
status, socioeconomic status), which may be associated with life satisfaction, SRH, or 
perceived bother, were not available in this study. 
Conclusions 
Symptom-based evaluation of QoL often contradicts with general QoL measures that are 
based on patients’ own perceptions of health and life satisfaction. The meanings, which 
patients attach to treatment side effects, and the extent to which they can adapt to those 
side effects over time, need more longitudinal and qualitative research [37, 41]. With a 
bigger sample and longer follow-up time, it would be possible to identify men that 
particularly benefited from pre-treatment counselling or other psychosocial services. 
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TABLE 1. Characteristics of study population. 
n (%) Md (Q₁, Q₃) 
Age, yrs 66 (62.0, 69.5) 
Gleason score 
≤ 6 53 (29.0 %) 
3+4 90 (49.2 %) 
4+3 27 (14.8 %) 
≥ 8 13 (7.1 %) 
T stage 
T2 113 (62.4 %) 
T3 68 (37.6 %) 
PSA level, µg/l 6.7 (5.2, 9.1) 
Margin status 
Positive 49 (27.5 %) 
Negative 129 (72.5 %) 
Percentage of cancer tissue in biopsy sample 10 (5.0, 20.0) 
Urinary function 76.8 (55.0, 93.4) 
Urinary bother 75.0 (50.0, 100.0) 
Sexual function 19.8 (6.3, 44.8) 
Sexual bother 25.0 (0.0, 75.0) 
Bowel function 93.8 (85.5, 93.8) 
Bowel bother 100.0 (75.0, 100.0) 
Did you have erectile dysfunction prior to cancer 
treatment? 
Often 15 (8.3 %) 
Sometimes 63 (35.0 %) 
Never 102 (56.7 %) 
Do you feel that you were given enough information 
and guidance about the disease and treatment? 
Yes 148 (83.6 %) 
No 29 (16.4 %) 
Overall, how satisfied are you with the cancer 
treatment you received? 
Very satisfied 73 (40.8 %) 
Satisfied 77 (43.0 %) 
I don't know 14 (7.8 %) 
Unsatisfied 5 (2.8 %) 
Very unsatisfied 10 (5.6 %) 
How would you rate your current health? 
Very good 21 (11.5 %) 
Fairly good 94 (51.4 %) 
Average 46 (25.1 %) 
Fairly poor 19 (10.4 %) 
Poor 3 (1.6 %) 
How satisfied are you with your present life? 
Very satisfied 29 (15.8 %) 
Satisfied 99 (54.1 %) 
Somehow satisfied 41 (22.4 %) 
Unsatisfied 9 (4.9 %) 
Very unsatisfied 4 (2.2 %) 
I don’t know 1 (0.5 %) 
TABLE 2. Association of explanatory variables to self-rated health and life satisfaction. 
Variables Self-rated health Life satisfaction 
Good SRH (n=115) Average or poor SRH (n=68) Clearly satisfied (n=128) Less satisfied (n=55) 
n (%) Md (Q₁, Q₃) n (%) Md (Q₁, Q₃) p-value n (%) Md (Q₁, Q₃) n (%) Md (Q₁, Q₃) p-value 
Age, yrs 67.0 (64.0, 70.0) 63.5 (58.3, 68.8) 0.001 67.0 (63.0, 70.0) 64.0 (60.0, 68.0) 0.013 
PSA level, µg/l 6.9 (5.3, 9.2) 6.2 (4.7, 8.2) 0.037 6.7 (4.8, 9.1) 6.7 (5.3, 9.1) 0.609 
Percentage of cancer 
tissue in biopsy 
sample, % 
7.0 (4.0, 15.0) 12.0 (6.0. 20.0) 0.005 8.0 (4.0, 16.5) 12.0 (7.0, 20.0) 0.006 
Gleason score 0.885 0.434 
≤ 6 33 (62.3 %) 20 (37.7 %) 40 (75.5 %) 13 (24.5 %) 
7 73 (62.4 %) 44 (37.6 %) 78 (66.7 %) 39 (33.3 %) 
≥ 8 9 (69.2 %) 4 (30.8 %) 10 (76.9 %) 3 (23.1 %) 
T stage 0.792 0.566 
T2 72 (63.7 %) 41 (36.3 %) 81 (71.7 %) 32 (28.3 %) 
T3 42 (61.8 %) 26 (38.2 %) 46 (67.6 %) 22 (32.4 %) 
Margin status 0.376 0.252 
Positive 28 (57.1 %) 21 (42.9 %) 31 (63.3 %) 18 (36.7 %) 
Negative 83 (64.3 %) 46 (35.7 %) 93 (72.1 %) 36 (27.9 %) 
Satisfaction with 
treatment 0.029 <0.001 
Clearly satisfied 102 (66.2 %) 52 (33.8 %) 116 (75.3 %) 38 (24.7 %) 
Less satisfied 13 (44.8 %) 16 (55.2 %) 12 (41.4 %) 17 (58.6 %) 
Sufficiency of patient 
guidance 0.005 
Sufficient 94 (63.5 %) 54 (36.5 %) 0.397 110 (74.3 %) 38 (25.7 %) 
Not sufficient 16 (55.2 %) 13 (44.8 %) 14 (48.3 %) 15 (51.7 %) 
Urinary function 81.8 (65.0, 100.0) 65.9 (42.1, 86.0) <0.001 81.8 (65.0, 100.0) 58.4 (28.4, 81.8) <0.001 
Urinary bother 75.0 (75.0, 100.0) 62.5 (25.5, 100.0) <0.001 75.0 (75.0, 100.0) 50.0 (25.0, 75.0) <0.001 
Sexual function 20.8 (6.3, 49.0) 17.7 (4.7, 30.3) 0.146 24.0 (6.8, 50.0) 16.6 (0.0, 29.1) 0.011 
Sexual bother 25.0 (0.0, 75.0) 25.0 (0.0, 56.3) 0.087 50.0 (0.0, 75.0) 0.0 (0.0, 25.0) <0.001 
Bowel function 93.8 (88.4, 100.0) 88.1 (75.9, 93.8) <0.001 93.8 (87.5, 100.0) 88.8 (75.5, 93.8) <0.001 
Bowel bother 100.0 (75.0, 100.0) 75.0 (50.0, 100.0) 0.001 100.0 (75.0, 100.0) 75.0 (50.0, 100.0) <0.001 
Pre-treatment erectile 
dysfunction 0.063 0.646 
Sometimes or often 43 (55.1 %) 35 (44.9 %) 56 (71.8 %) 22 (28.2 %) 
Never 70 (68.6 %) 32 (31.4 %) 70 (68.6 %) 32 (31.4 %) 
TABLE 3. Multivariate logistic regression models for self-rated health and life satisfaction. 
Variables Self-rated health Life satisfaction 
OR 95 % CI¹ p-value OR 95 % CI p-value 
Age 1.08 1.02-1.15 0.014 1.08 1.01-1.17 0.029 
PSA level 1.17 1.05-1.30 0.006 
Percentage of cancer tissue in biopsy 
sample 0.97 0.94-0.99 0.020 
Satisfaction with treatment 0.049 0.055 
Clearly satisfied 2.60 1.00-6.75 2.89 0.98-8.54 
Less satisfied 1.00 1.00 
Sufficiency of patient guidance 0.224 
Sufficient 1.94 0.67-5.64 
Not sufficient 1.00 
Urinary function 1.02 1.00-1.03 0.027 1.04 1.02-1.05 <0.001 
Sexual function 1.02 1.00-1.04 0.028 
Bowel function 1.03 1.00-1.06 0.074 1.02 0.99-1.06 0.121 
¹Confidence interval 
If a value is not presented in the table, the variable was not significantly related to the outcome variable in the 
univariate logistic regression. 
TABLE 4. Association of explanatory variables to UCLA PCI scores. 
Variables Urinary function Sexual function Bowel function 
r Md (Q₁, Q₃) p-value r Md (Q₁, Q₃) p-value r Md (Q₁, Q₃) p-value 
Age, yrs 0.108 -0.331 0.080 










Urinary/Sexual/Bowel bother 0.793 0.440 0.723 
Gleason score 0.965 0.043 0.983 
≤ 6 76.8 (55.4, 96.7) 29.1 (9.4, 54.7) 93.8 (85.5, 93.8) 
7 76.8 (53.4, 93.4) 16.6 (6.3, 41.6) 93.8 (81.9, 95.0) 
≥ 8 81.8 (64.2, 91.7) 15.6 (3.1, 29.1) 93.8 (85.5, 93.8) 
T stage 0.746 0.461 0.915 
T2 76.8 (58.4, 93.4) 21.9 (6.3, 49.0) 93.8 (85.5, 93.8) 
T3 79.3 (53.4, 93.4) 18.8 (6.3, 41.6) 93.8 (81.3, 100.0) 
Margin status 0.916 0.564 0.438 
Positive 81.8 (53.4, 90.9) 19.8 (1.6, 43.3) 93.8 (78.4, 97.5) 
Negative 76.8 (55.4, 93.4) 19.8 (6.3, 43.5) 93.8 (85.5, 93.8) 
Satisfaction with treatment 0.027 0.001 0.738 
Clearly satisfied 80.3 (55.0, 95.0) 22.9 (6.3, 48.9) 93.8 (85.5, 93.8) 
Less satisfied 65.0 (38.3, 84.6) 10.4 (0.0, 25.0) 93.8 (78.1, 100.0) 
Sufficiency of patient guidance 0.052 0.689 0.919 
Sufficient 80.0 (58.4, 95.0) 19.8 (6.3, 45.9) 93.8 (85.5, 93.8) 
Not sufficient 68.8 (48.4, 82.6) 19.3 (12.5, 29.1) 93.8 (85.5, 100.0) 
Pre-treatment erectile dysfunction <0.001 
Sometimes or often 9.9 (3.1, 24.8) 
Never 29.1 (13.5, 52.9) 
